(12R,25R)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacosane-2,7,13,24-tetraone | 548487-42-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯内酰胺
• 英文名称: (12R,25R)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacosane-2,7,13,24-tetraone
• 英文别名: (12R,25R)-14,23-dioxa-1,8-diazatricyclo[23.3.0.08,12]octacosane-2,7,13,24-tetrone
• CAS: 548487-42-9
• 化学式: C₂₄H₃₈N₂O₆
• 分子量: 450.576
• InChiKey: LWNWQUXDIOITSD-WOJBJXKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  32
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  93.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (12R,25R)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacos-18-ene-2,7,13,24-tetraone 在 钯 作用下， 以 乙酸乙酯 为溶剂， 以yielded 245 mg (61%) (12R,25R)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacosane-2,7,13,24-tetraone as a white solid, MS m/e (%)的产率得到(12R,25R)-14,23-dioxa-1,8-diaza-tricyclo[23.3.0.0 8,12]octacosane-2,7,13,24-tetraone
  参考文献：
  名称：

  New D-proline prodrugs

  摘要：

  本发明涉及具有以下式1的化合物： 其中，R1和R2分别独立地表示低烷氧基、低烯氧基、苄氧基、羟基、—OCH(CH3)OC(O)-低烷基或—OCH2C(O)N(R3)(R4)，但仅有R1或R2可以是羟基；R3和R4独立地表示氢、低烷基、低烯基或环烷基；或者R1和R2与它们所连接的碳原子一起形成连接基X，其中X为—O(CH2)nCH═CH(CH2)nO—或—O(CH2)mO—；n为1、2或3；m为4-8；或者该化合物的药学上可接受的盐。 本发明的化合物可用于治疗血清淀粉样蛋白P成分耗竭对疾病具有有益影响的情况，特别是用于治疗或预防中枢和全身淀粉样变性。

  公开号：

  US20030134891A1

文献信息

• D-proline prodrugs
  申请人：Huwyler Joerg

  公开号：US06903129B2

  公开（公告）日：2005-06-07

  The invention relates to compounds of formulas wherein R 1 and R 2 are independently from each other lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, —OCH(CH 3 )OC(O)-lower alkyl or —OCH 2 C(O)N(R 3 )(R 4 ), with the proviso that only one of R 1 or R 2 may be hydroxy; R 3 and R 4 are independently from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R 1 and R 2 form together with the carbon atom, to which they are attached the linking group X, wherein X is —O(CH 2 ) n CH═CH(CH 2 ) n O— or —O(CH 2 ) m O—; n is 1, 2 or 3; and m is 4-8, or a pharmaceutically acceptable salt of said compound. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of central and systemic amyloidosis.

  本发明涉及以下式的化合物： 其中，R1和R2独立地为较低的烷氧基、较低的烯氧基、苄氧基、羟基、-OCH(CH3)OC(O)-较低的烷基或-O C(O)N(R3)(R4)，但仅有R1或R2可以是羟基；R3和R4独立地表示氢、较低的烷基、较低的烯基或环烷基；或者R1和R2与它们所连接的碳原子一起形成连接基X，其中X为-O(CH2)nCH═CH( )nO-或-O( )mO-；n为1、2或3；m为4-8；或者该化合物的药学上可接受的盐。 本发明的化合物可用于治疗血清淀粉样蛋白P成分耗竭对疾病有益的疾病，特别是在中枢和全身淀粉样变性的治疗或预防中。
• Progrugs to d-prolines
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1743884A1

  公开（公告）日：2007-01-17

  The invention relates to compounds of formulae wherein R1 and R2 are independently from each other and signify lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, ―OCH(CH3)OC(O)-lower alkyl or ―OCH2C(O)N(R3)(R4), with the proviso that only one of R1 or R2 may be hydroxy; R3 and R4 are independently from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R1 and R2 form together with the carbon atom, to which they are attached the linking group X, wherein X is ―O(CH2)nCH=CH(CH2)nO- or -O(CH2)mO-; n is 1, 2 or 3; and m is 4-8. as well as pharmaceutically acceptable salts of said compounds. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of all forms of central and systemic amyloidosis.

  本发明涉及如下式的化合物 其中 R1和R2彼此独立，分别表示低级烷氧基、低级烯氧基、苄氧基、羟基、-OCH(CH3)OC(O)-低级烷基或-O C(O)N(R3)(R4)，但R1或R2中只能有一个是羟基； R3 和 R4 相互独立，表示氢、低级烷基、低级烯基或环烷基；或 R1 和 R2 与连接它们的碳原子一起形成连接基团 X，其中 X 是-O(CH2)nCH=CH( )nO-或-O( )mO-； n 是 1、2 或 3；以及 m 为 4-8。 以及上述化合物的药学上可接受的盐类。本发明的化合物可用于治疗血清淀粉样蛋白 P 成分消耗具有有益效果的疾病，特别是用于治疗或预防各种形式的中枢性和全身性淀粉样变性。
• PRODRUGS TO D-PROLINES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1458680A1

  公开（公告）日：2004-09-22
• US6903129B2
  申请人：——

  公开号：US6903129B2

  公开（公告）日：2005-06-07
• [EN] PRODRUGS TO D-PROLINES<br/>[FR] PROMEDICAMENTS DE D-PROLINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003051836A1

  公开（公告）日：2003-06-26

  The invention relates to compounds of formulae (I) or (IA), wherein R?1 and R2¿ are independently from each other and signify lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, -OCH(CH¿3?)OC(O)-lower alkyl or OCH2C(O)N(R?3)(R4¿), with the proviso that only one of R1 or R2 may be hydroxy; R?3 and R4¿ are independently from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R?1 and R2¿ form together with the carbon atom, to which they are attached the linking group X, wherein X is -O(CH¿2?)nCH=CH(CH2)n0- or -O(CH2)mO-; n is l, 2 or 3; and m is 4-8. as well as pharmaceutically acceptable salts of said compounds. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of all forms of central and systemic amyloidosis.